1.
Journal summary
During the 2023, we had 46 submissions, 28 published papers. Of these, 17 were research articles, 8 were review articles. Authors were most often from USA, Espain, UK, Italy, Germany, Brazil, France, Japan, China, India and other countries. The percent of the international collaborations is rising.
An important part of our strategy has been preparation of special issues. In 2023, three Special Issue were planned, we hope these three Special Issue can continue to attract the author's contributions. AIMS Bioengineering have invited 7 experts to join our Editorial Board in 2023. We will continue to renew Editorial Board in 2024.
For the next year I hope we can increase the number of high quality submissions to this journal, while maintaining a rigorous review process. We also have a number of actions planned which we hope will enable further development to strengthen the presence, quality and sustainability of our journal. For example, issuance of more popular special issues, renewal of the Editorial Board and reduction of processing time. We will be seeking the support of the Editorial Board members to make this plan a success.
I would like to end this report by thanking all the members of the journal's Editorial Team and Board. The continued growth seen in 2023 was due to your hard work and I look forward to working with you to further build the strength and reputation of our journal in 2024.
The AIMS Bioengineering Editorial Office
Springfield, MO 65801-2604, USA
2.
Editorial development
2.1. Manuscript statistics
The submissions of our AIMS Bioengineering journal in 2023 down slightly. The journal AIMS Bioengineering began accepting submissions in 2023 and in the past year, it received 46 submissions. Of those, 28 were submitted online, 19 were rejected. The Median Publication time in 2023 (from submission to online) is 70.5 days.
![]()
Submission: 46
Online: 28
Rejection: 19
Reject rate: 41%
Median Publication time (from submission to online): 70.5 days
2.2. Author distribution
Author country of origin distribution is shown below. It is pleasing to see so many countries represented among our authors. The following Chart shows that the majority of authors of AIMS Bioengineering online manuscripts in 2023 are from America, Asia and Europe which accounts for more than half of all publications.
![]()
2.3. Article type
The table below lists the article type of published articles.
2.4. Article metrics
2.5. Special issue completed with the most papers
An important part of our strategy has been preparation of special issues. We encourage Editorial Board members to suggest potential topics and to act as guest editors of special issues. The following three Special Issue were established in 2023, we hope these three Special Issue can continue to attract the author's contributions in 2024.
The following two special issues which were established in 2022 are cases with a relatively high degree of completion in the 2023. There are several reasons why these two special issues can be relatively successful.
1. The topic is more suitable and attracts contributions from the right authors.
2. The special issue guest editors is also more responsible, able to make timely decisions on manuscripts, without delaying the processing progress of manuscripts
Special Issue:
Surveillance of elderlies at home: sensors, portable medical imaging devices, medical data management on smart phone
Special issue editor: Professor Jacques Demongeot and Oshinubi Kayode
http://www.aimspress.com/aimsboa/article/6350/special-articles
New biomaterials for bone augmentation in complicated cases
Special issue editor: Professor José Luis Calvo Guirado
http://www.aimspress.com/aimsboa/article/6314/special-articles
2.6. Editorial Board members
AIMS Bioengineering has 53 Editorial Board members, 7 of which joined in 2023. Importantly, we thank all Editorial Board members for their hard work throughout the year, and it is noted that many Editorial Board members made significant contributions to our journal. We will continue to renew Editorial Board in 2024.
2.7. Summary & plan
2.7.1. Summary
In 2023, our journal developed smoothly. We have received more than 45 submissions and published 28 papers in 2023.
The IF grades came out, the comprehensive impact factor of our journals in the past five years is 2.2. The 2022 Impact Factor is 2.3. Starting in the second half of 2023, ESCI journal also has Journal Impact Factors, and we will continue to take this opportunity to elevate our journal AIMS Bioengineering to a higher level with the joint efforts of the editorial board, editors, and contributing authors in the 2024.
2.7.2. Plan for 2023
In order to distribute the knowledge, quality science and to enhance the scope of our newly launched journal we need support from eminent professionals. With this in mind, our first action for 2024 is to renew the Editorial Board. This renewal has two parts: (1) invitation of leading scholars in the field of Bioengineering to join the Board; and (2) removal of members who have become inactive.
Our second action for 2024 is to invite high reputation and professional authors to submit manuscript for our journal. We will try to invite more high-quality articles (Research and review), especially the review. And we plan to increase the proportion of articles from developed countries. This has been targeted for some time and we feel that 2024 is the year for their introduction.
The third action is to edit more popular special issues associated with hot topics on Bioengineering around the world. This will attract more submissions from authors studying Bioengineering. Increase influence by soliciting and advertising high quality articles and special issues (topics).
The fourth action is to improve the journal influence. We strive to have our journals indexed by all top databases, including web of science, Scopus, Pubmed, etc. We seek to be indexed in Scopus in 2024. We also strive to maximize exposure to high-quality articles in a variety of ways in order to provide good science and knowledge.
DownLoad:
